Company profile

Novartis AG

Pipeline62 assets

LutatheraAAA601 / Lutathera / SSTR / Radioligand therapy / Oncology: Solid Tumors
Gastroenteropancreatic neuroendocrine tumorsPhase 3Supplementary; filing 2028GEPNET, pediatricsPhase 2
177Lu-NeoBAAA603 / GRPR / Radioligand therapy / Oncology: Solid Tumors
Breast cancerPhase 1Multiple solid tumorsPhase 2Lead; filing >= 2029
AAA614FAP / Radioligand therapy / Oncology: Solid Tumors
Solid tumorsPhase 2Lead
PluvictoAAA617 / Pluvicto / PSMA / Radioligand therapy / Oncology: Solid Tumors
Oligometastatic prostate cancerPhase 3Supplementary; filing >= 2029Metastatic hormone sensitive prostate cancer (mHSPC)RegistrationSupplementary
225Ac-PSMA-617AAA817 / PSMA / Radioligand therapy / Oncology: Solid Tumors
Metastatic castration-resistant prostate cancer (mCRPC)Phase 3Supplementary; filing >= 2029post Lu Metastatic castration-resistant prostate cancer (mCRPC)Phase 3Lead; filing 2028
ScemblixABL001 / Scemblix / BCR-ABL / Inhibitor / Oncology: Hematology
Chronic myeloid leukemia, pediatricsPhase 2Supplementary; filing 2027
CosentyxAIN457 / Cosentyx / IL17A / Inhibitor / Immunology
Polymyalgia rheumaticaRegistrationSupplementary; filing 2026
AimovigAMG334 / Aimovig / CGRPR / Antagonist / In-market Brands and Global Health
Migraine, pediatricsPhase 3Supplementary; filing 2028
AMO959DNA PK / Inhibitor / Oncology: Solid Tumors
Prostate cancerPhase 1Lead
MayzentBAF312 / Mayzent / S1P1,5 receptor modulator / Neuroscience
Multiple sclerosis, pediatricsPhase 3Supplementary; filing 2027
VijoyceBYL719 / Vijoyce / PI3K-alpha / Inhibitor / Oncology: Solid Tumors
Lymphatic malformationsPhase 3Supplementary; filing >= 2029
farabursenCYX082 / MIR17 / Inhibitor / Cardiovascular, Renal and Metabolic
Autosomal dominant polycystic kidney diseasePhase 1Lead
pelabresibDAK539 / BET / Inhibitor / Oncology: Hematology
MyelofibrosisPhase 3Lead; filing 2026
DFT383CTNS gene delivery / Neuroscience
CystinosisPhase 1Lead
DII235siRNA targeting Lp(a) MRNA / Cardiovascular, Renal and Metabolic
CVRR-Lp(a)Phase 2Lead; filing >= 2029
del-braxDWH213 / siRNA DUX4 knockdown / Neuroscience
Facioscapulohumeral muscular dystrophyPhase 3Lead; filing 2028
tulmimetostatDZR123 / EZH1, EZH2 / Inhibitor / Oncology: Solid Tumors
Metastatic prostate cancerPhase 1Solid tumors & lymphomasPhase 2Lead
ECI830CDK2 / Inhibitor / Oncology: Solid Tumors
Breast cancerPhase 1Lead
EDI048CpPI(4)K / Inhibitor / In-market Brands and Global Health
CryptosporidiosisPhase 2Lead
EDK060Lead Indication / Neuroscience
Charcot-Marie-Tooth diseasePhase 1
ESP359DLL3 / Radioligand therapy / Oncology: Solid Tumors
Solid tumorsPhase 1Lead
del-desiranEWF980 / siRNA DMPK knockdown / Neuroscience
Myotonic dystrophy type 1Phase 3Lead; filing 2027
EYU688NS4B / Inhibitor / In-market Brands and Global Health
Dengue feverPhase 2Lead
zigakibartFUB523 / Anti-APRIL / Cardiovascular, Renal and Metabolic
IgA nephropathyPhase 3Lead; filing 2027
177Lu-NNS309FXX489 / FAP / Radioligand therapy / Oncology: Solid Tumors
Solid tumorsPhase 1Lead
GCJ904Lead Indication / Oncology: Solid Tumors
Solid tumorsPhase 1
GHZ339Lead Indication / Immunology
Atopic dermatitisPhase 2filing >= 2029
GIA632IL-15 mAb / Immunology
Atopic dermatitisPhase 2Lead; filing >= 2029VitiligoPhase 2Supplementary; filing >= 2029
GXV813M4 / Agonist / Neuroscience
SchizophreniaPhase 2Lead
HJB647Lead Indication / Cardiovascular, Renal and Metabolic
Heart failurePhase 1
votoplamHTT227 / Huntingtin modulator / Neuroscience
Huntington’s diseasePhase 3Lead; filing >= 2029
INE963Plasmodium falciparum / Inhibitor / In-market Brands and Global Health
MalariaPhase 2Lead
IPX643Lead Indication / Immunology
Inflammation-driven diseasesPhase 1
ITU512HbF inducing agent / In-market Brands and Global Health
Sickle cell diseasePhase 1Lead
luxdegalutamideJSB462 / Androgen receptor protein degrader / Oncology: Solid Tumors
Metastatic hormonal sensitive prostate cancerPhase 2Metastatic castration resistant prostate cancerPhase 2Lead; filing >= 2029
cipargaminKAE609 / PfATP4 / Inhibitor / In-market Brands and Global Health
Malaria, uncomplicatedPhase 2Supplementary; filing >= 2029Malaria severePhase 2Lead; filing >= 2029
LeqvioKJX839 / Leqvio / siRNA (regulation of LDL-C) / Cardiovascular, Renal and Metabolic
CVRR (primary prevention)Phase 3Supplementary; filing >= 2029CVRR (secondary prevention)Phase 3Supplementary; filing 2027
Ganaplacide + lumefantrineKLU156 / Non-artemisinin plasmodium falciparum / Inhibitor / In-market Brands and Global Health
Malaria, uncomplicatedPhase 3Lead; filing 2026
del-zotaKPE179 / PMO mediated exon 44 skipping / Neuroscience
Duchenne muscular dystrophyPhase 2Lead; filing 2026
FabhaltaLNP023 / Fabhalta / CFB / Inhibitor / Neuroscience / Cardiovascular, Renal and Metabolic / Oncology: Hematology / Others
Generalized myasthenia gravisPhase 3Supplementary; filing 2027C3 glomerulopathy, pediatricsPhase 3IgAN, pediatricsPhase 3
RhapsidoLOU064 / Rhapsido / BTK / Inhibitor / Immunology
Chronic spontaneous urticaria, pediatricsPhase 3Hidradenitis suppurativaPhase 3Supplementary; filing 2027Chronic inducible urticaria (CINDU)Phase 3Supplementary; filing 2026
remibrutinibLOU064 / BTK / Inhibitor / Neuroscience
Multiple sclerosis, secondary progressivePhase 3Supplementary; filing >= 2029Myasthenia gravisPhase 3Supplementary; filing 2028Multiple sclerosis, relapsing remittingPhase 3Supplementary; filing 2027
LTP001SMURF1 / Inhibitor / Cardiovascular, Renal and Metabolic
Idiopathic pulmonary fibrosisPhase 2Pulmonary arterial hypertensionPhase 2Lead; filing >= 2029
LXE408Proteasome / Inhibitor / In-market Brands and Global Health
ChagasPhase 2Visceral leishmaniosisPhase 2Lead; filing >= 2029
abelacimabMAA868 / FXI / Inhibitor / Cardiovascular, Renal and Metabolic
Atrial fibrillationPhase 3Lead; filing 2028
MAS825IL18 Inhibitor, IL1B / Immunology
Still’s diseasePhase 2Lead
NIO752Tau antisense oligonucleotide / Neuroscience
Alzheimer’s diseasePhase 1Progressive supranuclear palsyPhase 1Lead
OJR520Lead Indication / Cardiovascular, Renal and Metabolic
CKDPhase 1
KesimptaOMB157 / Kesimpta / CD20 / Antagonist / Neuroscience
Multiple sclerosis, new dosing regimenPhase 3Supplementary; filing 2027Multiple sclerosis, pediatricsPhase 3Supplementary; filing 2026
PAC001Anti-IL-6 mAb / Cardiovascular, Renal and Metabolic / Others
ASCVD pacibekitugPhase 2Lead; filing >= 2029Thyroid eye disease (TED) pacibekitugPhase 2
PIT565Anti-CD19, Anti-CD2, Anti-CD3 / Immunology
Systemic lupus erythematosusPhase 1Rheumatoid arthritisPhase 1
RydaptPKC412 / Rydapt / Multi-targeted kinase / Inhibitor / In-market Brands and Global Health
Acute myeloid leukemia, pediatricsPhase 2Supplementary; filing 2027
PKN605HDAC6 / Inhibitor / Cardiovascular, Renal and Metabolic
Atrial FibrillationPhase 2Lead
QCZ484Lead Indication / Cardiovascular, Renal and Metabolic
HypertensionPhase 2filing >= 2029
AtecturaQMF149 / Atectura / LABA + ICS / In-market Brands and Global Health
Asthma, pediatricsPhase 3Supplementary; filing >= 2029
AdakveoSEG101 / Adakveo / P-selectin / Inhibitor / In-market Brands and Global Health
Sickle cell disease, pediatricsPhase 3Supplementary; filing >= 2029
TIN816ATP modulator / Cardiovascular, Renal and Metabolic
Acute kidney injuryPhase 2Lead
pelacarsenTQJ230 / ASO targeting Lp(a) / Cardiovascular, Renal and Metabolic
CVRR (secondary prevention) in patients with elevated Lp(a)Phase 3Lead; filing 2026
ianalumabVAY736 / BAFF-R inhibitor, ADCC-mediated B-cell depletor / Immunology / Oncology: Hematology
Lupus NephritisPhase 3Supplementary; filing 2028Systemic lupus erythematosus (SLE)Phase 3Supplementary; filing 2028Systemic sclerosisPhase 2Supplementary; filing 2028
VHB937TREM2 stabilizer and activator / Neuroscience
Amyotrophic lateral sclerosisPhase 2Lead; filing >= 2029Alzheimer's diseasePhase 2Supplementary; filing >= 2029
YMI024Lead Indication / Cardiovascular, Renal and Metabolic
CVRRPhase 1
rapcabtagene autoleucelYTB323 / CD19 CAR-T / Immunology / Neuroscience / Oncology: Hematology
Rheumatoid arthritis and severe, refractory Sjögren’s diseasePhase 1Systemic sclerosisPhase 2Supplementary; filing >= 2029MyositisPhase 2Supplementary; filing >= 2029

Latest news25 items

May 26, 2026

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

Basel, May 26, 2026 – Novartis will present data from 15 abstracts from its kidney portfolio at this year’s European Renal Association (ERA) Congress in Glasgow, June 3-6. The presentations reinforce our ambition to advance scientific understanding across progressive immune-mediated kidney diseases and support the evolution of kidney care.

Presentation / Abstract • Phase 3ERA Late-breaker oral presentation Thu, Jun 4, 2026, 12:30 PM BST

May 21, 2026

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress.

Presentation / Abstract • Phase 3ASCO oral presentation Sat, May 30, 2026, 1:15 PM CDT

May 17, 2026

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto ® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC)....

Presentation / Abstract • Phase 3AUA rapid oral presentation Sun, May 17, 2026

May 7, 2026

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest milestone in its broader $23 billion investment in US manufacturing and research....

Apr 30, 2026

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Basel, April 30, 2026 – Novartis today announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient (API) manufacturing for solid dosage tablets, capsules and RNA therapeutics....

Apr 28, 2026

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Ad hoc announcement pursuant to Art. 53 LR First quarter

Apr 27, 2026

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Basel, April 27, 2026 – Novartis announced today that the European Commission (EC) approved Rhapsido ® (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1-antihistamine treatment....

Apr 24, 2026

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

Basel, April 24, 2026 – Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Itvisma ® (intrathecal onasemnogene abeparvovec)....

Apr 24, 2026

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

Basel, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from 2 to 5 kilograms....

Apr 9, 2026

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Basel, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This comes as public health efforts against chronic diseases slow or reverse in many countries....

Mar 29, 2026

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta ® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo 1...

Trial Results • Phase 3

Mar 27, 2026

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression - Exl-111 would complement existing Novartis portfolio in allergy with potential...

Mar 23, 2026

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s American Academy of Dermatology (AAD) Annual Meeting.

Presentation / Abstract • Phase 3

Mar 20, 2026

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Basel, March 20, 2026 – Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a next-generation approach for the treatment of patients with HR+/HER2- breast cancer and potentially other solid tumor indications.

Mar 13, 2026

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Basel, March 13, 2026 – Novartis announced today that Cosentyx ® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor for this population 1 ....

Mar 6, 2026

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

Basel, March 6, 2026 – Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the company’s Annual General Meeting (AGM). A total of 1 554 shareholders were present at the meeting held in Basel, representing approximately 59.15% of the issued shares of Novartis....

Feb 27, 2026

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. (“Avidity”). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis.

Feb 27, 2026

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for remibrutinib....

Feb 25, 2026

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

Basel, February 25 , 2026 – Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas....

Feb 24, 2026

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

Basel, February 24, 2026 – Novartis today announced multiple US real-world studies delivering new insights across metastatic prostate cancer care. The analyses utilize data from Novartis’ PRECISION platform to evaluate Pluvicto™ (lutetium ( 177 Lu) vipivotide tetraxetan) effectiveness and sequencing as well as real‑world treatment patterns in earlier...

Feb 23, 2026

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton’s tyrosine kinase inhibitor (BTKi) Rhapsido ® (remibrutinib) in chronic spontaneous urticaria (CSU) and as an investigational therapy for peanut allergy at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in...

Presentation / Abstract • Phase 2

Feb 18, 2026

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

Basel, February 18, 2026 – Novartis today announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU) 1 . The primary endpoint was met for the three most prevalent types of CIndU:...

Trial Results • Phase 3

Feb 13, 2026

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia ® (atrasentan). Vanrafia showed a difference of 2.39 ml/min/1.73m 2 in estimated glomerular filtration rate (eGFR) change from baseline vs....

Trial Results • Phase 3

Feb 6, 2026

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical Research center in San Diego, California, designed to provide world-class scientific infrastructure and drug-discovery capabilities to advance the company’s pipeline for patients....

Feb 4, 2026

Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

Ad hoc announcement pursuant to Art. 53 LR